Long-term use of mood stabilizers and its impact on the quality of life of chinese patients with schizophrenia

Clinical Neuropharmacology

Volumn 32, Issue 1, 2009, Pages 16-21

  Xiang, Yu Tao ^a,b,c   Weng, Yong Zhen ^a   Leung, Chi Ming ^b   Tang, Wai Kwong ^b   Ungvari, Gabor S ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c SHATIN HOSPITAL   (Hong Kong)

Author keywords

China (Clin Neuropharm 2009; 32: 16Y21); Mood stabilizers; Quality of life; Schizophrenia

Indexed keywords

CARBAMAZEPINE; LITHIUM; MOOD STABILIZER; VALPROIC ACID;

ADULT; ARTICLE; CHINA; CHINESE; CONTROLLED STUDY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HONG KONG; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; SCHIZOPHRENIA;

ADULT; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CHI-SQUARE DISTRIBUTION; DRUG PRESCRIPTIONS; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; OUTPATIENTS; QUALITY OF LIFE; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 67749086623     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e31815d25b5     Document Type: Article

References (44)

1. Chou JC. Recent advances in treatment of acute mania. J Clin Psychopharmacol 1991;11:3-21.
2. Chen H, Kennedy WK, Dorfman JH, et al. The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia. Curr Med Res Opin 2007;23:1351-1365.
3. Citrome L. Use of lithium, carbamazepine, and valproic acid in a state-operated psychiatric hospital. J Pharm Technol 1995;11:55-59.
4. Siris SG. Adjunctive medication in the maintenance treatment of schizophrenia and its conceptual implications. Br J Psychiatry 1993;163(suppl 22):66-78.
5. Parepally H, Chakravorty S, Levine J, et al. The use of concomitant medications in psychiatric inpatients treated with either olanzapine or other antipsychotic agents: a naturalistic study at a state psychiatric hospital. Prog Neuropsychopharmacol Biol Psychiatry 2002;26: 437-440.
6. Citrome L, Levine J, Allingham B. Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. Psychiatr Serv 2000;51:634-638.
7. Citrome L, Jaffe A, Levine J, et al. Use of mood stabilizers among patients with schizophrenia, 1994-2001. Psychiatr Serv 2002;53:1212.
8. Clark RE, Bartels SJ, Mellman TA, et al. Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophr Bull 2002;28:75-84.
9. Pinikahana J, Happell B, Hope J, et al. Quality of life in schizophrenia: a review of the literature from 1995 to 2000. Int J Ment Health Nurs 2002;11:103-111.
10. Weng YZ, Xu MJ, Li DL, et al. Assessment of expressed emotion in family members of schizophrenic patients in Beijing. Mod Rehabil 2001;5:39-42.
11. Xiang YT, Weng YZ, Leung CM, et al. Quality of life of Chinese schizophrenia outpatients in Hong Kong: relationship to sociodemographic factors and symptomatology. Aust N Z J Psychiatry 2007;41:442-449.
12. Xiang YT, Weng YZ, Leung CM, et al. Clinical and social determinants of antipsychotic polypharmacy for Chinese patients with schizophrenia. Pharmacopsychiatry 2007;40:47-52.
13. APA. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
14. Lobana A, Mattoo SK, Basu D, et al. Quality of life in schizophrenia in India: comparison of three approaches. Acta Psychiatr Scand 2001;104:51-55.
15. Kane JM. Schizophrenia. N Engl J Med 1996;334:34-41.
16. Sim K, Su A, Leong JY, et al. High dose antipsychotic use in schizophrenia: findings of the REAP (research on east Asia psychotropic prescriptions) study. Pharmacopsychiatry 2004;37:175-179.
17. Shen WL, Shi GW, Song LS, et al. The impact of long-term use of lithium on thyroid function [in Chinese]. Shanghai Arch Psychiatry 1997;9:72-74.
18. Overall JE, Beller SA. The Brief Psychiatric Rating Scale (BPRS) in geropsychiatric research: I. Factor structure on an inpatient unit. J Gerontol 1984;39:187-193.
19. Shin SK, Lukens EP. Effects of psychoeducation for Korean Americans with chronic mental illness. Psychiatr Serv 2002;53:1125-1131.
20. Bechdolf A, Klosterkotter J, Hambrecht M, et al. Determinants of subjective quality of life in post acute patients with schizophrenia. Eur Arch Psychiatry Clin Neurosci 2003;253:228-235.
21. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11-19.
22. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-676.
23. Rudnick A, Kravetz S. The relation of social support-seeking to quality of life in schizophrenia. J Nerv Ment Dis 2001;189:258-262.
24. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
25. Fang JQ, Hao YT, Li CX. Reliability and validity for Chinese version of WHO quality of life scale [in Chinese]. Chinese Ment Health J 1999;13:203-205.
26. WHO. The World Health Organization Quality of Life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med 1995;41:1403-1409.
27. Sim K, Su A, Chan YH, et al. Clinical correlates of antipsychotic polytherapy in patients with schizophrenia in Singapore. Psychiatry Clin Neurosci 2004;58:324-329.
28. Kovacs G. Prescription of psychotropic drugs for schizophrenic outpatients in Hungary. Neuropsychopharmacol Hung 2005;7:4-10.
29. Castle D, Morgan V, Jablensky A. Antipsychotic use in Australia: the patients' perspective. Aust N Z J Psychiatry 2002;36:633-641.
30. Mallinger JB, Lamberti SJ. Racial differences in the use of adjunctive psychotropic medications for patients with schizophrenia. J Ment Health Policy Econ 2007;10:15-22.
31. Qin P, Mortensen PB. Specific characteristics of suicide in China. Acta Psychiatr Scand 2001;103:117-121.
32. Ran MS, Xiang MZ, Mao WJ, et al. Characteristics of suicide attempters and nonattempters with schizophrenia in a rural community. Suicide Life Threat Behav 2005;35:694-701.
33. Shen YC. Psychiatry. Beijing: People's Medical Publishing House; 2002:671-677.
34. Haw C, Stubbs J. A survey of the off-label use of mood stabilizers in a large psychiatric hospital. J Psychopharmacol 2005;19:402-407.
35. Chai HX, Du JH, Wu ZJ. A study of additive effect of sodium valproate in the treatment of schizophrenia [in Chinese]. J Clin Psychol Med 2004;14:151-152.
36. Wang CY, Luo XN, Liu RG, et al. The influence of violent behavior on patients with psychiatric disorder [in Chinese]. Health Psychol 1995;3:21-22.
37. Chinese Medical Association. Guideline for the Prevention and Treatment of Mental Disorder. Beijing: China Medical Association; 2003.
38. Miller DS, Yatham LN, Lam RW. Comparative efficacy of typical and atypical antipsychotics as add-on therapy to mood stabilizers in the treatment of acute mania. J Clin Psychiatry 2001;62:975-980.
39. Eronen M. Mental disorders and homicidal behavior in female subjects. Am J Psychiatry 1995;152:1216-1218.
40. Buchanan RW, Kreyenbuhl J, Zito JM, et al. Relationship of the use of adjunctive pharmacological agents to symptoms and level of function in schizophrenia. Am J Psychiatry 2002;159:1035-1043.
41. Glick ID, Pham D, Davis JM. Concomitant medications may not improve outcome of antipsychotic monotherapy for stabilized patients with nonacute schizophrenia. J Clin Psychiatry 2006;67: 1261-1265.
42. Misra M, Papakostas GI, Klibanski A. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J Clin Psychiatry 2004;65:1607-1618 [quiz 1590, 1760-1601].
43. Ginsberg DL, Schooler NR, Buckley PF, et al. Optimizing treatment of schizophrenia. Enhancing affective/cognitive and depressive functioning. CNS Spectr 2005;10:1-13 [discussion 14-15].
44. Ungvari GS, Chow LY, Chiu HF, et al. Modifying psychotropic drug prescription patterns: a follow-up survey. Psychiatry Clin Neurosci 1997;51:309-314.